Reply to 'Comment on: Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizmab'

Eye (Lond). 2016 May;30(5):766-7. doi: 10.1038/eye.2016.6. Epub 2016 Feb 12.

Authors

T D Papakostas¹, D Vavvas¹, D Eliott¹, L A Kim¹

Affiliation

¹ Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.

No abstract available

Publication types

Letter
Comment

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Bevacizumab
Humans
Intravitreal Injections
Macular Edema*
Retinal Vein Occlusion*
Treatment Outcome
Vascular Endothelial Growth Factor A / therapeutic use
Visual Acuity

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Vascular Endothelial Growth Factor A
Bevacizumab